Vaishali Shukla
Vice President, CGT & API Global Expansion Eli Lilly & Co.
Vaishali Shukla is a proven leader with expertise in quality and in developing the teams required to deliver it.
In her current role as VP, of Quality at Lilly, Vaishali leads API and CGT manufacturing sites. In this role, Vaishali oversees functional and site strategies, setting overarching goals and objectives as well as developing and executing short- and long-term strategic direction.
With more than 20 years of experience in the biopharmaceutical industry, she is an expert in a broad variety of subjects ranging from early clinical development to commercialization of Cell and Gene therapy, Peptide, ADC, biologics & small molecules.
Vaishali’s career includes work at BioVest International, Takeda Pharmaceuticals, Shire Pharmaceuticals, UniQure, and Kite where she implemented novel processes for continuous development.
With a BS in Biology, master’s degrees in Botany, Regulatory Affairs, Pharmaceutical Economics and Policy, and a Ph.D. in Pharmaceutical Science.
Vaishali lives in the Indianapolis area and is the proud mother of her daughter Smita, who is following her footsteps as a female trailblazer in the biosciences.
Seminars
- How are emerging mRNA modalities in CGT changing the biggest process development and CMC challenges teams need to solve today?
- Where are current analytical and control strategies falling short when applied across diverse mRNA-enabled CGT applications – and how should they evolve?
- What does a truly scalable and flexible CMC framework look like when supporting multiple mRNA-driven CGT modalities with differing requirements?
